Explore All Access
Check if your research matches the topics covered in Current Cancer Drug Targets?
- Degree of match
- Common matching concepts
- Additional journal recommendations
Current Cancer Drug Targets : Impact Factor & More
eISSN: 1873-5576pISSN: 1568-0096
Share this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Aims and Scope
Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Ruiwen Zhang (UH Drug Discovery Institute). The journal covers research on contemporary molecular drug targets involved in cancer, including medicinal chemistry, pharmacology, molecular biology, genomics, and biochemistry. Current Cancer Drug Targets publishes original research reports, review papers, and rapid communications ("letters"). Less
Current Cancer Drug Targets Key Metrics
CiteScore 
6.4
H-Index
99
Impact Factor
< 5
SJR
Q2Oncology
SNIP
0.85
Topics Covered on Current Cancer Drug Targets
Cancer
Carcinogenesis
Assay
Chemotherapy
Lung cancer
Breast cancer
Reactive oxygen species
Autophagy
Immunotherapy
Cell activation
Colorectal cancer
Drug resistance
Temozolomide
Tumor growth
RNA editing
Prostate cancer
Hepatocellular carcinoma
Oxime
Tumor progression
Immune system
Current Cancer Drug Targets Journal Specifications
| Overview | |
| Publisher | BENTHAM SCIENCE PUBL LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 2000 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Current Cancer Drug Targets ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Current Cancer Drug Targets
Future Cancer Drug Discovery Is Now
- 1 Jan 2025
- Current Cancer Drug Targets
Acknowledgement to Reviewers
- 1 Dec 2024
- Current Cancer Drug Targets
Role of NADPH Quinone Reductase 1 (NQO1) Polymorphism in Prevention, Diagnosis, and Treatment of Gastrointestinal Cancers.
- 1 Dec 2024
- Current Cancer Drug Targets
The Role of Local Angiotensin II/Angiotensin Type 1-receptor Mechanisms in Adipose Tissue Dysfunction to Promote Pancreatic Cancer.
- 1 Dec 2024
- Current Cancer Drug Targets
Hybrid Nanoparticle for Co-delivering Paclitaxel and Dihydroartemisinin to Exhibit Synergic Anticancer Therapeutics.
- 1 Dec 2024
- Current Cancer Drug Targets
The Prognostic Value and Clinical Significance of lncRNA SNHG5 Expression in Patients with Multiple Malignancies: A Bioinformatic and Meta-analysis.
- 1 Dec 2024
- Current cancer drug targets
Future Cancer Drug Discovery Is Now
- 1 Jan 2025
- Current Cancer Drug Targets
Acknowledgement to Reviewers
- 1 Dec 2024
- Current Cancer Drug Targets
Role of NADPH Quinone Reductase 1 (NQO1) Polymorphism in Prevention, Diagnosis, and Treatment of Gastrointestinal Cancers.
- 1 Dec 2024
- Current Cancer Drug Targets
The Role of Local Angiotensin II/Angiotensin Type 1-receptor Mechanisms in Adipose Tissue Dysfunction to Promote Pancreatic Cancer.
- 1 Dec 2024
- Current Cancer Drug Targets
Hybrid Nanoparticle for Co-delivering Paclitaxel and Dihydroartemisinin to Exhibit Synergic Anticancer Therapeutics.
- 1 Dec 2024
- Current Cancer Drug Targets
The Prognostic Value and Clinical Significance of lncRNA SNHG5 Expression in Patients with Multiple Malignancies: A Bioinformatic and Meta-analysis.
- 1 Dec 2024
- Current cancer drug targets
Compare Similar Journals with Current Cancer Drug Targets
Select Journals to Compare with Current Cancer Drug Targets
Total journals - 10
You can select up to 3 Journals at a time
Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
Frontiers in Oncology
Publisher: FRONTIERS MEDIA SA
Cancers
Publisher: MDPI
Oncotarget
Publisher: Impact Journals
International Journal of Molecular Sciences
Publisher: MDPI
Scientific Reports
Publisher: NATURE PORTFOLIO
Oncology Letters
Publisher: SPANDIDOS PUBL LTD
OncoTargets and Therapy
Publisher: DOVE MEDICAL PRESS LTD
Annals of Oncology
Publisher: ELSEVIER
BMC Cancer
Publisher: BMC
0 Journals Selected to compare with
Current Cancer Drug Targets
Compare journals across 7 parameters SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
Get detailed Journal comparison report on your email by signing up
FAQs on Current Cancer Drug Targets
How long has Current Cancer Drug Targets been actively publishing? 
Current Cancer Drug Targets has been in operation since 2000 till date.
What is the publishing frequency of Current Cancer Drug Targets?
Current Cancer Drug Targets published with a Monthly frequency.
How many articles did Current Cancer Drug Targets publish last year?
In 2023, Current Cancer Drug Targets publsihed 81 articles.
What is the eISSN & pISSN for Current Cancer Drug Targets?
For Current Cancer Drug Targets, eISSN is 1873-5576 and pISSN is 1568-0096.
What is Citescore for Current Cancer Drug Targets?
Citescore for Current Cancer Drug Targets is 6.4.
What is the H Index for Current Cancer Drug Targets ?
H Index for Current Cancer Drug Targets is 99.
What is SNIP score for Current Cancer Drug Targets?
SNIP score for Current Cancer Drug Targets is 0.85.
What is the SJR for Current Cancer Drug Targets?
SJR for Current Cancer Drug Targets is Q2.
Who is the publisher of Current Cancer Drug Targets?
BENTHAM SCIENCE PUBL LTD is the publisher of Current Cancer Drug Targets.
